Anagenics Past Earnings Performance

Past criteria checks 0/6

Anagenics has been growing earnings at an average annual rate of 10.4%, while the Personal Products industry saw earnings growing at 8.7% annually. Revenues have been growing at an average rate of 8.7% per year.

Key information

10.4%

Earnings growth rate

45.3%

EPS growth rate

Personal Products Industry Growth-25.2%
Revenue growth rate8.7%
Return on equity-268.8%
Net Margin-67.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Dec 17
How Much is Cellmid's (ASX:CDY) CEO Getting Paid?

Revenue & Expenses Breakdown

How Anagenics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:AN1 Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2411-770
31 Mar 2410-570
31 Dec 2310-370
30 Sep 2310-260
30 Jun 239-260
31 Mar 239-160
31 Dec 229-170
30 Sep 228-170
30 Jun 227-270
31 Dec 216-360
30 Sep 216-360
30 Jun 216-460
31 Dec 206-570
30 Sep 207-580
30 Jun 207-480
31 Mar 208-481
31 Dec 198-481
30 Sep 197-591
30 Jun 197-6101
31 Mar 197-691
31 Dec 186-681
30 Sep 186-571
30 Jun 186-461
31 Mar 186-461
31 Dec 176-461
30 Sep 175-461
30 Jun 175-461
31 Mar 174-460
31 Dec 164-360
30 Sep 164-360
30 Jun 163-360
31 Mar 163-451
31 Dec 153-451
30 Sep 152-441
30 Jun 152-341
31 Mar 152-341
31 Dec 141-331
30 Sep 142-231
30 Jun 142-131
31 Mar 142-131
31 Dec 132-131

Quality Earnings: AN1 is currently unprofitable.

Growing Profit Margin: AN1 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AN1 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.

Accelerating Growth: Unable to compare AN1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AN1 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (10.2%).


Return on Equity

High ROE: AN1 has a negative Return on Equity (-268.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/26 17:32
End of Day Share Price 2024/08/29 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anagenics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stuart RobertsPitt Street Research Pty Ltd.